• PSY5 FACTORS ASSOCIATED WITH SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY

    Nov 1, 2008, 00:00

  • PUK3 THE COST ADVANTAGE OF INCREASING THE USE OF PERITONEAL DIALYSIS IN TURKEY

    Nov 1, 2008, 00:00

  • PRS22 ARE THE MEASUREMENT PROPERTIES OF THE ASTHMA QUALITY OF LIFE QUESTIONNAIRE (AQLQ) CONSISTENT ACROSS LANGUAGES?

    Nov 1, 2008, 00:00

  • MS3 POPULATION HEALTH-STATE UTILITIES FOR FIBROMYALGIA IN THE UNITED KINGDOM

    Nov 1, 2008, 00:00

  • PRS16 THE HOSPITALIZATION COST OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN THE UNIVERSITY HOSPITAL OF ALEXANDROUPOLIS, GREECE

    Nov 1, 2008, 00:00

  • PMH51 DECLINE IN DEPRESSION TREATMENT PERSISTS AFTER FDA ANTIDEPRESSANTWARNINGS

    Nov 1, 2008, 00:00

  • PRS5 ESTABLISHING THE INCIDENCE AND PREVALENCE OF MULTIPLE A TOPIC CONDITIONS IN UK- COHORT STUDY USING THE GENERAL PRACTICE RESEARCH DATABASE

    Nov 1, 2008, 00:00

  • PMS32 THE DIRECT HEALTH CARE COSTS OF OSTEOARTHRITIS- EVIDENCE FROM US NATIONAL SURVEY DATA

    Nov 1, 2008, 00:00

  • PCV44 COST-EFFECTIVENESS MODEL OF IMPLANTABLE CARDIAC MONITORS (ICM) FOR PATIENTS TREATED WITH RADIOFREQUENCY CATHETER ABLATION FOR A TRIAL FIBRILLATION (PAAF) IN SPAIN

    Nov 1, 2008, 00:00

  • PMH54 INDICATION SPECTRUM OF SNRI APPLIED FOR THE TREATMENT OF DEPRESSION-A PHARMACOEPIDEMIOLOGICAL ANALYSIS OF CLAIMS DATA OF A GERMAN SICKNESS FUND

    Nov 1, 2008, 00:00

  • CN1 PHARMACOECONOMIC APPLICATIONS IN FORMULARY MANAGEMENT- BUDGET IMPACT ANALYSIS OF PACLITAXEL PROTEIN-BOUND AT A MAJOR CANCER CENTER

    Nov 1, 2008, 00:00

  • PSY30 HEALTH CARE RESOURCE USE AND COSTS AMONG PATIENTS WITH DIABETIC NEUROPATHIC PAIN IN THE ONE-YEAR FOLLOWING DULOXETINE THERAPY- IS INITIAL DOSING A SIGNIFICANT FACTOR?

    Nov 1, 2008, 00:00

  • PCV78 ANEURYSM OCCLUSION IN ELDERLY PATIENTS WITH ANEURYSMAL SUBARACHNOID HAEMORRHAGE- A COST-UTILITY ANALYSIS

    Nov 1, 2008, 00:00

  • PSS37 IDENTIFYING NON COMPLIANT GLAUCOMA PATIENTS USING THE EDSQ, A QUESTIONNAIRE MEASURING SATISFACTION AND COMPLIANCE OF GLAUCOMA TREATMENT

    Nov 1, 2008, 00:00

  • PMH3 RISPERIDONE LONG-ACTING INJECTION (RLAI) IN THE TREATMENT OF SCHIZOPHRENIA- 3 MONTH PRELIMINARY RESULTS FROM THE ELECTRONIC SCHIZOPHRENIA TREATMENT ADHERENCE REGISTRY (E-STAR) IN RUSSIA

    Nov 1, 2008, 00:00

  • PUK5 COST-BENEFITS ANALYSIS OF DIET VERSUS DIALYSIS IN ELDERLY CKD5 PATIENTS

    Nov 1, 2008, 00:00

  • PCN68 COST-UTILITY ANALYSIS OF DOCETAXEL VERSUS STANDARD REGIMEN IN THE NEOADJUVANT THERAPY OF LOCALLY ADVANCED BREAST CANCER IN POLAND

    Nov 1, 2008, 00:00

  • PCN23 COST EFFECTIVENESS OF CLODRONATE AND ZOLENDRONATE FOR THE TREATMENT OF METASTATIC BONE DISEASE IN BRAZIL- PUBLIC HEALTH PERSPECTIVE

    Nov 1, 2008, 00:00

  • QL5 COMPARISON OF EQ-5D AND HUI3 IN PATIENTS WITH TINNITUS

    Nov 1, 2008, 00:00

  • PMS2 DIAGNOSIS OF OSTEOPOROSIS BY DUAL X-RAY AND LASER (DXL) DENSITOMETRY-A HEALTH TECHNOLOGY ASSESSMENT

    Nov 1, 2008, 00:00

  • PG128 DEVELOPMENT AND PSYCHOMETRIC VALIDATION OF A NEW QUESTIONNAIRE MEASURING THE IMPACT OF CHILD GASTROENTERITIS ON PARENTS

    Nov 1, 2008, 00:00

  • PND25 EVALUATION OF A BRIEF DEMENTIA SCREENING TEST FOR PARKINSONS DISEASE (PD-BDST) IN A CLINICAL PRACTICE SETTING

    Nov 1, 2008, 00:00

  • QL11 FATIGUE REDUCTION AND PHYSICAL FUNCTION IMPROVEMENTS ASSOCIATED WITH INCREASED PRODUCTIVITY AT WORK AND AT HOME IN RHEUMATOID ARTHRITIS PATIENTS

    Nov 1, 2008, 00:00

  • PMS1 COGNITIVE IMPAIRMENT IN PATIENTS WITH FIBROMYALGIA SYNDROME AS ASSESSED BY THE MINIMENTAL STATE EXAMINATION

    Nov 1, 2008, 00:00

  • PDB39 IS INSULIN GLARGINE A COST EFFECTIVE OPTION IN TREATMENT OF PATIENTS WITH TYPE DM1 WITH BASELINE HBA1C ABOVE 8 IN COMPARISON TO NPH AND PREMIX IN POLAND?

    Nov 1, 2008, 00:00

  • PSS35 COST UTILITY OF BILATERAL COCHLEAR IMPLANT

    Nov 1, 2008, 00:00

  • QL7 INTERPRETING SCORES ON THREE COPD PATIENT-REPORTED OUTCOME MEASURES

    Nov 1, 2008, 00:00

  • PCV43 MODELED COST-EFFECTIVENESS OF ACHIEVING MULTIPLE LIPID TARGETSWHEN FENOFIBRIC ACID IS CO-ADMINISTERED WITH SIMVASTATIN, ROSUVASTATIN, AND ATORVASTATIN

    Nov 1, 2008, 00:00

  • PIN47 VALIDATION OF THE SINONASAL OUTCOMETEST-16 (SNOT-16) IN PATIENTS WITH ACUTE BACTERIAL SINUSITIS

    Nov 1, 2008, 00:00

  • PCV57 ESTIMATING THE NUMBER AND COST OF CARDIOVASCULAR EVENTS AVOIDED BY TREATING TO ALTERNATIVE LDL-C TARGETS- IS LOWER BETTER?

    Nov 1, 2008, 00:00

  • PSS38 RELATION BETWEEN SELF REPORTED GLAUCOMA SYMPTOMS AND COMPLIANCE

    Nov 1, 2008, 00:00

  • PCV27 MODELING THE FISCAL IMPACT OF USING PERFLUTREN LIPID MICROSPHERES (PLM) FOR FOLLOW-UP ECHOCARDIOGRAPHIC IMAGING

    Nov 1, 2008, 00:00

  • PSY2 CONTRIBUTIONS OF THE FABRY OUTCOME SURVEY (FOS) TO ADVANCING THE MANAGEMENT OF FABRY DISEASE

    Nov 1, 2008, 00:00

  • PMS45 OUTPATIENT MEDICAL MANAGEMENT OF FIBROMYALGIA IN FRANCE COMPARED TO THE UNITED KINGDOM

    Nov 1, 2008, 00:00

  • PCV120 GLYCOPROTEIN INHIBITOR USE IN ACUTE CORONARY SYNDROME PATIENTS IN 2007- RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL STUDY (APTOR)

    Nov 1, 2008, 00:00

  • PCV9 AN ANALYSIS OF THE ANTIHYPERTENSIVE EFFECTIVENESS OF IRBESARTANVS. CANDESARTAN

    Nov 1, 2008, 00:00

  • PSY12 COST-EFFECTIVENESS OF FOOD FOR SPECIAL MEDICAL PURPOSES RELATIVE TO STANDARD CARE IN PATIENTS UNDERGOING ABDOMINAL SURGERY

    Nov 1, 2008, 00:00

  • PG131 GENDER, AGE AND BODY MASS-RELATED DIFFERENCES IN THE IMPACT OF GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD) SYMPTOMS IN PRIMARY CARE PATIENTS ASSESSED BY THE GASTROINTESTINAL IMPACT SCALE (GIS)

    Nov 1, 2008, 00:00

  • PCN33 ECONOMIC EVALUATION OF FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER (MCRC) BASED ON IRINOTECAN (FOLFIRI) BEVACIZUMAB OR CETUXIMAB, ADJUSTED BY KRAS GENE (WILD-TYPE (WT) OR MUTANT (MT))

    Nov 1, 2008, 00:00

  • PDB25 COST EFFECTIVENESS ANALYSIS OF HUMAN PREMIX INSULIN REGIMENS COMPARED WITH A PREMIX ANALOGUE INSULIN IN THE PRIVATE HEALTH CARE SECTOR IN SOUTH AFRICA

    Nov 1, 2008, 00:00

  • PSY62 A NATURAL EXPERIMENT TO ESTIMATE THE IMPACT OF A PREFERRED DRUG LIST POLICY FOR LONG ACTING NARCOTIC ANALGESICS ON COSTS AND UTILIZATION

    Nov 1, 2008, 00:00

  • PSY21 COST-MINIMIZATION ANALYSIS OF ORALVS. INTRAVENOUS FLUDARABINE (BENEFLUR) IN SPAIN

    Nov 1, 2008, 00:00

  • PCV12 AN ANALYSIS OF THE ANTIHYPERTENSIVE EFFECTIVENESS OF ARBS VS. ACE INHIBITORS

    Nov 1, 2008, 00:00

  • PSS16 SENSITIVE SKINS IN GERMANY- AN EPIDEMIOLOGICAL APPROACH

    Nov 1, 2008, 00:00

  • PCV122 MODELING THE EFFECT OF DIFFERENTIAL COMPLIANCE WITH ANTIHYPERTENSIVE DRUGS ON CLINICAL ENDPOINTS

    Nov 1, 2008, 00:00

  • PMS3 A COMPARISON OF CLINICAL EFFICACY OF LEFLUNOMIDE VS OTHER THERAPUETIC OPTIONS IN THE TREATEMENT OF RHEUMATOID ARTHRITIS

    Nov 1, 2008, 00:00

  • PSS7 A MIXED TREATMENT COMPARISON OF TOPICAL OCULAR HYPOTENSIVES FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION

    Nov 1, 2008, 00:00

  • PHP22 COMPARATIVE ANALYSIS OF HOSPITAL BED CAPACITITES OF OLD (EU-15) AND NEW (EU-12) MEMBERSTATES OF THE EUROPEAN UNION

    Nov 1, 2008, 00:00

  • PIH24 ASSESSMENT OF CURRENT CLINICAL PRACTICE AMONG PHYSICIANS AND SEX THERAPISTS REGARDING ERECTILE DYSFUNCTION (ED) TREATMENT INITIATION WITH PHOSPHODIESTERASE-5 INHIBITORS (PDE5I)

    Nov 1, 2008, 00:00

  • MH6 ADHERENCE, PERSISTENCE, COSTS AND QUALITY OF LIFE IN PATIENTS TREATED WITH ANTIPSYCHOTIC DRUGS- RESULTS FROM THE COMETA STUDY

    Nov 1, 2008, 00:00

  • PSY32 COSTS OF A BLOODTRANSFUSION IN HEMATO-ONCOLOGIC PATIENTS IN A PORTUGUESE HOSPITAL

    Nov 1, 2008, 00:00

  • PRS25 THE PUBLICS WILLINGNESS TO PAY FOR A QALY IN THAILAND

    Nov 1, 2008, 00:00

  • PCV65 COSTS OF BLEEDS ASSOCIATED WITH TREATING ACUTE CORONARY SYNDROME PATIENTS IN GERMANY

    Nov 1, 2008, 00:00

  • PDB60 A COMPARISON OF THE MANAGEMENT OF SEVERE HYPOGLYCAEMIA IN INSULIN-TREATED DIABETES IN THREE EUROPEAN COUNTRIES- SIMILARITIES, DIFFERENCES AND RESOURCE IMPLICATIONS

    Nov 1, 2008, 00:00

  • PCN85 PATIENT PREFERENCES IN THE THERAPY OF MULTIPLE MYELOMA

    Nov 1, 2008, 00:00

  • PND12 COSTS OF HERPES ZOSTER AND POST-HERPETIC NEURALGIA IN FRANCE

    Nov 1, 2008, 00:00

  • PIN52 UTILIZATION ANALYSIS AND IMPACT OF ANTIBACTERIAL AGENTS IN TWO LEADING UNIVERSITY HOSPITALS IN NEIGHBORING COUNTRIES WITH DIFFERENT GDP AND HEALTH CARE SYSTEM

    Nov 1, 2008, 00:00

  • PDB9 ESTIMATED INCIDENCE OF TESTOSTERONE DEFICIENCY IN AGING BRAZILIAN MEN AND THE CONSEQUENT COSTS OF NEW CASES OF OSTEOPOROSIS-RELATED HIP FRACTURES

    Nov 1, 2008, 00:00

  • PMS13 IMPACT OFVIOXX WITHDRAWAL ON VOLUME OF TOTAL HIP AND KNEE REPLACEMENTS

    Nov 1, 2008, 00:00

  • PHP6 CLINICAL AND ECONOMIC OUTCOME OF MECHANICALLY VENTILATED PATIENTS UNDER DRG 483 IN SPAIN- A POPULATION-BASED STUDY

    Nov 1, 2008, 00:00

  • PCN44 COST MINIMIZATION ANALYSIS OF ADVANCED GASTRIC CANCERTREATMENT WITH CAPECITABINE/CISPLATIN (XP) VS. 5-FU/CISPLATIN (FP) REGIMENS IN POLISH SETTING

    Nov 1, 2008, 00:00

  • PCV94 PREDICTORS OF HEALTH STATUS CHANGE AMONG PATIENTS TREATED WITH A CALCIUM ANTAGONISTOR AN ATENOLOL-LED HYPERTENSION STRATEGY IN THE INTERNATIONAL VERAPAMIL SR-TRANDOLAPRIL STUDY (INVEST)

    Nov 1, 2008, 00:00

  • QL6 ROLE OF DISEASE SPECIFIC INSTRUMENTS IN THE MEASUREMENT OF HEALTH-RELATED QUALITY OF LIFE IN CANCER CLINICAL TRIALS

    Nov 1, 2008, 00:00

  • PRS3 PREVALENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE FROM ADMINISTRATIVE HEATH SERVICES DATABASES

    Nov 1, 2008, 00:00

  • PCV59 INPATIENT RESOURCE USE ASSOCIATED WITHTHE TREATMENT OF SECONDARY A TRIAL FIBRILLATION

    Nov 1, 2008, 00:00

  • PCN52 ECONOMIC ANALYSIS OF ERLOTINIB, DOCETAXEL, PEMETREXED AND BEST SUPPORTIVE CARE AS 2ND OR 3RD LINE TREATMENT OF NON-SMALL CELL LUNG CANCER

    Nov 1, 2008, 00:00

  • PSY42 E-DIARY COMPLIANCE IN ACUTE PAIN STUDIES

    Nov 1, 2008, 00:00

  • PCV89 THE COST EFFECTIVENESS OF PERSISTENCE TO ANTIHYPERTENSIVE TREATMENT

    Nov 1, 2008, 00:00

  • PND21 SYMPTOM SEVERITY IN PARKINSONS DISEASE SEVERITY

    Nov 1, 2008, 00:00

  • PCV2 UNDERUSE OF STATINES AMONG HIGH RISK PATIENTS

    Nov 1, 2008, 00:00

  • PCV97 TREATMENTS FOR VARICOSE VEIN DISEASE- EXPECTATIONS AND EXPERIENCES OF PATIENTS

    Nov 1, 2008, 00:00

  • PG13 PHARMACOECONOMIC ASSESSMENT OF LANREOTIDE IN THE MANAGEMENT OF POST-OPERATIVE DIGESTIVE FISTULAS

    Nov 1, 2008, 00:00

  • PMH17 TREATMENT OF OPIATE DEPENDENT PATIENTS INWALES WITH BUPRENORPHINE/NALOXONE-A COST-EFFECTIVENESS EVALUATION

    Nov 1, 2008, 00:00

  • PCV24 BUDGET IMPACT OF GUIDELINE ADHERENT THERAPY IN ACUTE CORONARY SYNDROME (ACS) IN GERMANY

    Nov 1, 2008, 00:00

  • Disclosure Information

    Nov 1, 2008, 00:00

  • PMS35 RHEUMATOID ARTHRITIS COST STUDY RESULTS IN POLAND

    Nov 1, 2008, 00:00

  • PMC40 STABILITY OF TREATMENT SATISFACTION WITH MEDICINES QUESTIONNAIRE (SATMED-Q) STRUCTURE IN DIFFERENT PATHOLOGY SAMPLES

    Nov 1, 2008, 00:00

  • PG115 COSTS OF CROHNS DISEASE WITHIN THE GERMAN STATUTORY HEALTH INSURANCE

    Nov 1, 2008, 00:00

  • PRS41 USE OF AN ELECTRONIC DIARY IN 55 COUNTIRES- WHAT ARE THE CHALLENGES?

    Nov 1, 2008, 00:00

  • PG19 THE COST-EFFECTIVENESS OF HIGH-DOSE INTRAVENOUS ESOMEPRAZOLE IN PEPTIC ULCER BLEEDING- A DECISION-TREE MODEL WITH SPANISH COSTS AND NEW CLINICAL DATA

    Nov 1, 2008, 00:00

  • PSY44 UNDERSTANDING AND ASSESSING THE IMPACT OF PRESCRIPTION WEIGHT LOSS MEDICATION; CONCEPTUAL, GENDER AND CULTURAL ISSUES

    Nov 1, 2008, 00:00

  • PCN102 THE BURDEN OF RENAL CELL CANCER- A RETROSPECTIVE LONGITUDINAL STUDY ON OCCURRENCE, OUTCOMES AND COST USING AN ADMINISTRATIVE CLAIMS DATABASE

    Nov 1, 2008, 00:00

  • PUK18 VALIDATION OF THE URINARY SENSATION SCALE (USS)

    Nov 1, 2008, 00:00

  • MD4 UNCOVERING ATRIAL FIBRILLATION (AF) IN PATIENTS WITH STROKE OF UNDETERMINED AETIOLOGY- COST-EFFECTIVENESS OF ADDING IMPLANTABLE CARDIAC MONITORS (ICMS) TO THE DIAGNOSTIC PATHWAY

    Nov 1, 2008, 00:00

  • PIN5 IMPACT OF MASS VACCINATION WITH MMRV VERSUS MMR IN FRANCE ON THE EPIDEMIOLOGY OF VARICELLA AND HERPES ZOSTER, USING A DYNAMIC TRANSMISSION MODEL

    Nov 1, 2008, 00:00

  • PHP44 IN EQUALITIES IN THE FINANCING OF DRUGS AMONG AUTONOMOUS REGIONS IN SPAIN

    Nov 1, 2008, 00:00

  • PUK8 FESOTERODINE IS COST-EFFECTIVE FOR THE TREATMENT OF OVERACTIVE BLADDER- RESULTS OF AN ECONOMIC MODEL

    Nov 1, 2008, 00:00

  • PG136 SELF-DIAGNOSIS AND HEALTH SEEKING BEHAVIOUR OF WOMEN FOR MINOR BOWL AILMENTS IN A LARGE REPRESENTATIVE UNITED KINGDOM (UK) SAMPLE POPULATION

    Nov 1, 2008, 00:00

  • PDB33 COST COMPARISON OF INSULIN GLARGINE AND INSULIN DETEMIR IN TYPE 2 DIABETES MELLITUS IN ARGENTINA- A TRIAL-BASED PROBABILISTIC MODEL

    Nov 1, 2008, 00:00

  • PDB35 COST-UTILITY ANALYSIS OF BIPHASIC INSULIN ASPART VERSUS HUMAN INSULIN IN TYPE 2 DIABETES MELLITUS PATIENTS TREATED IN TIER III HOSPITALS IN BEIJING, CHINA- A LONGTERM OUTCOMES MODEL EVALUATION FROM THE IMPROVE OBSERVATIONAL STUDY

    Nov 1, 2008, 00:00

  • PRS26 THE EXACT-PRO INITIATIVE- DEVELOPMENT AND VALIDATION OF A SINGLE PATIENT-REPORTED OUTCOME MEASURE FOR EVALUATING EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    Nov 1, 2008, 00:00

  • PUK2 IN GREECE, INCREASING THE UTILIZATION OF PERITONEAL DIALYSIS THERAPY MAY REDUCE OVERALL DIALYSIS EXPENDITURES

    Nov 1, 2008, 00:00

  • PG137 A COMPARISON OF TREATMENT FAILURE RATES BASED ON STARTING ALGINATE THERAPY OBSERVED IN A LARGE REPRESENTATIVE LONGITUDINAL UK DATABASE

    Nov 1, 2008, 00:00

  • PCN7 ANALYSIS AND CATEGORISATION OF DRUG-RELATED PROBLEMS ASSOCIATED WITH SYSTEMIC BREAST CANCER THERAPY

    Nov 1, 2008, 00:00

  • PMS44 PARAMEDICAL OR ALTERNATIVE TREATMENTS AND ASSOCIATED COSTS FOR THE MANAGEMENT OF FIBROMYALGIA IN FRANCE

    Nov 1, 2008, 00:00

  • PCN59 ECONOMIC BURDEN OF TREATING VIN AND VAIN 2/3 IN GERMANY

    Nov 1, 2008, 00:00

  • PCN100 CONSUMPTION AND ACCESS TO INNOVATIVE CANCER DRUGS IN SLOVAKIA

    Nov 1, 2008, 00:00

  • PUK19 PSYCHOMETRIC EVALUATION OF THE KHQ IN TEN LANGUAGES

    Nov 1, 2008, 00:00

  • PDB61 CHART AUDIT OF THE DOSE AND EFFECTIVENESS OF LONG ACTING INSULIN ANALOGUES IN AUSTRALIAN CLINICAL PRACTICE

    Nov 1, 2008, 00:00

  • PG117 REALWORLD DOSING OF ANTI-TUMOR NECROSIS FACTOR THERAPIES IN THE TREATMENT OF ADULTS WITH CROHNS DISEASE

    Nov 1, 2008, 00:00

  • PCN20 COST-EFFECTIVENESS ANALYSIS OF ADJUVANT TRASTUZUMAB FOR TREATMENT OF HER2-POSITIVE EARLY BREAST CANCER IN THE SAUDI ARABIAN SETTING

    Nov 1, 2008, 00:00

  • PSY17 PRECISE STUDY- BASELINE ANALYSIS OF A COST EFFECTIVENESS STUDY ON FAILED BACK SURGERY SYNDROME

    Nov 1, 2008, 00:00

  • QL2 TRANSLATION OF THE COLUMBIA SUICIDE SEVERITY RATING SCALE (C-SSRS) FOR USE IN 33 COUNTRIES

    Nov 1, 2008, 00:00

  • PDB49 HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND TREATMENT SATISFACTION (TS) IN DIABETIC PATIENTS ATTENDED IN SPANISH PRIMARY CARE CENTRES

    Nov 1, 2008, 00:00

  • PSY39 IMPACT OF HIGHWAIST CIRCUMFERENCE ON PRODUCTIVITY IN US AND GERMAN OVERWEIGHT/OBESE SUBJECTS

    Nov 1, 2008, 00:00

  • PCN50 COST-MINIMIZATION ANALYSIS OF ERLOTINIB VERSUS DOCETAXEL OR PEMETREXED AS A SECOND-LINE TRETAMENT OF ADVANCED NON-SMALL LUNG CANCER (NSCLC) IN THE CONDITIONS OF THE CZECH REPUBLIC

    Nov 1, 2008, 00:00

  • PSS24 SYSTEMATIC REVIEW AND META-ANALYSIS OF RCTS REGARDING THE COMPARATIVE INCIDENCE OF HYPERAEMIA OF PROSTAGLANDIN TOPICAL GLAUCOMA MEDICATIONS

    Nov 1, 2008, 00:00

  • PCV109 PRESCRIPTION DRUG INSURANCE AND EX ANTE MORAL HAZARD

    Nov 1, 2008, 00:00

  • PG139 ALEGRIA, A REAL LIFE EVALUATION OF GERD (GASTROESOPHAGEAL REFLUX DISEASE) IMPACT OF SYMPTOM ASSESSMENT IN LUXEMBOUR

    Nov 1, 2008, 00:00

  • PRS30 HOW CONGRUENT ARE PATIENT AND CLINICIAN MODELS OF ASTHMA CONTROL?-PRELIMINARY FINDINGS FROM A QUALITATIVE STUDY

    Nov 1, 2008, 00:00

  • PCV69 COST-EFFECTVENESS OF ENDOVASCULAR ANEURYSM REPAIR VERSUS OPEN SURGICAL REPAIR- NON-RUPTURED INFRARENAL ABDOMINAL AORTIC ANEURYSM IN AN ELECTIVE SETTING

    Nov 1, 2008, 00:00

  • PSY29 TREATMENT COST OF FEBRILE NEUTROPENIA (FN) IN PATIENTS WITH ACUTE LEUKEMIA (AL) OR IN AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) RECIPIENTS FROM THE GERMAN HOSPITALS PERSPECTIVE

    Nov 1, 2008, 00:00

  • PSS49 A DISEASE MODEL ILLUSTRATING THE IMPACT OF PSORIASIS ON PATIENTS LIVES

    Nov 1, 2008, 00:00

  • PRS4 SUB-ACUTE LACK OF ASTHMA CONTROL AS A PREDICTOR OF ASTHMA EXACERBATION IN A MANAGED CARE POPULATION

    Nov 1, 2008, 00:00

  • PMC61 THE IMPLICIT VALUE OF STATISTICAL LIFE- ESTIMATES DERIVED FROM PUBLIC INTERVENTIONS IMPLEMENTED IN THE NETHERLANDS

    Nov 1, 2008, 00:00

  • PHP59 LABEL CLAIMS BASED ON PATIENT REPORTED OUTCOMES IN EMEA AND FDA APPROVALS SINCE 2000

    Nov 1, 2008, 00:00

  • PHP40 INVESTIGATING THE PROMOTION OF HEALTH BEHAVIOR AND HEALTH-RELATED QUALITY OF LIFE BY APPLYING SELF-DETERMINATION THEORY- USING 'EXERCISE' AS AN EXAMPLE

    Nov 1, 2008, 00:00

  • PHP42 EVALUATION OF THE AFTERNOON OUTPATIENT CLINICS OPERATION AT THE UNIVERSITY HOSPITAL IN LARISA

    Nov 1, 2008, 00:00

  • PMS66 WILLINGNESS TO PAY VS. QUALITY ADJUSTEDWAGES AS ALTERNATIVE WAYS TO MEASURE THE BURDEN OF DISEASE IN SPAIN- AN APPLICATION TO BALLOON KYPHOPLASTY

    Nov 1, 2008, 00:00

  • PMH42 HEALTH-RELATED QUALITY OF LIFE OF MARRIED, WORKING WOMEN WITH CHILDREN (SUPERWOMAN SYNDROME) IN KOREA

    Nov 1, 2008, 00:00

  • PDB29 ESTIMATING THE DIRECT COST OF TYPE II DIABETES IN GREECE

    Nov 1, 2008, 00:00

  • PDB27 INSULIN GLARGINE AND NPH INSULIN-BASED REGIMENS REVEAL COMPARABLE TOTAL DIRECT TREATMENT COSTS IN TYPE 2 DIABETES PATIENTS.THE LONG-ACTING INSULIN GLARGINE VS. NPH INSULIN COST EVALUATION STUDY IN GERMANY (LIVE-DE)

    Nov 1, 2008, 00:00

  • PHP31 IS PATENT PROTECTION CREATING OPPORTUNITY FOR INNOVATION?-THE ALENDRONATE CASE IN BELGIUM

    Nov 1, 2008, 00:00

  • PHP35 PHARMACEUTICAL EXPENDITURE IN GREECE 1980-2006

    Nov 1, 2008, 00:00

  • PCV11 EFFECTIVENESS OF DRUG-ELUTING STENTS VS. BARE METAL STENTS UNRESTRICTED USE IN PATIENTS WITH CORONARY HEART DISEASE IN SOCIAL SECURITY MEXICAN INSTITUTE

    Nov 1, 2008, 00:00

  • PSY25 SYSTEMATIC REVIEW OF THE COST OF ILLNESS OF SYSTEMIC LUPUS ERYTHEMATOSUS

    Nov 1, 2008, 00:00

  • PUK4 PHARMACOECONOMIC EVALUATION OF SOLIFENACIN IN THE TREATMENT OF OVERACTIVE BLADDER SYNDROME IN ITALY

    Nov 1, 2008, 00:00

  • PMH32 A GPRD STUDY OF HEALTH CARE COST ASSOCIATED WITH DIFFERENT FIRST-LINE ANTIDEPRESSANT TREATMENTS IN SEVERE DEPRESSION

    Nov 1, 2008, 00:00

  • PCV92 DERIVING UTILITY VALUES FOR ACUTE CORONARY SYNDROMES FROM THE GENERAL POPULATION IN AUSTRALIA

    Nov 1, 2008, 00:00

  • PIN3 A SIMULATION-BASED APPROACH TO MODELING THE EFFECTS OF INTERVENTION STRATEGIES ON THE SPREAD OF MENINGOCOCCAL MENINGITIS

    Nov 1, 2008, 00:00

  • PCV108 RISK AND COSTS OF THE FIRST HYPERTENSION-ASSOCIATED EVENT, COMPLIANCE AND PERSISTENCE IN NAVE HYPERTENSIVE PATIENTS AFTER INITIATING MONOTHERAPY

    Nov 1, 2008, 00:00

  • PSS53 A TOPIC DERMATITIS IN PAEDIATRIC PATIENTS- COMMON CAREGIVER BEHAVIOURWHEN FACING THE DIFFERENT DISEASE PRESENTATIONS OR LESION SEVERITY. ELIBROT STUDY

    Nov 1, 2008, 00:00

  • PCN47 ECONOMIC EVALUATION IN THE POSTOPERATIVE MANAGEMENT OF COLORECTAL CANCER PATIENTS IN GREECE

    Nov 1, 2008, 00:00

  • QL10 DEVELOPMENT AND VALIDATION OF THE SATISFACTION WITH MEDICATION QUESTIONNAIRE (SAT-Q) IN PATIENTS WITH CHRONIC DISEASE

    Nov 1, 2008, 00:00

  • PMC50 THE SUITABILITY OF VISUAL ANALOGUE SCALES (VAS) FOR COLLECTING PATIENT-REPORTED OUTCOMES (PRO) DATA FROM INTERNATIONAL SETTINGS

    Nov 1, 2008, 00:00

  • PND23 RELATIONSHIP BETWEEN CHANGES IN EQ-5D DERIVED UTILITY SCORES AND CHANGES IN IRLS SUM SCORES FROM A MAPPING EXERCISE IN TWO PHASE III CLINICAL TRIALS

    Nov 1, 2008, 00:00

  • PUK20 VALIDATION OF THE SPANISH VERSION OF THE PELVIC ORGAN PROLAPSE/URINARY INCONTINENCE SEXUAL QUESTIONNAIRE-SHORT FORM (PISQ-12)

    Nov 1, 2008, 00:00

  • PRS8 TOTAL COSTS OF TOBACCO FOR SOCIETY-WHAT ARE THE RETURNS ON INVESTMENTS FOR DIFFERENT GOVERNMENTAL INTERVENTIONS?

    Nov 1, 2008, 00:00

  • PCN51 POTENTIAL ECONOMIC AND HEALTH IMPACT OF GENOMICS AND PROTEOMICSTECHNOLOGY FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA

    Nov 1, 2008, 00:00

  • PRS15 ESTIMATING EXCESS COSTS OF POPULATION-BASED CASES WITH MILD COPD-RESULTS FROM THE KORA F3 STUDY

    Nov 1, 2008, 00:00

  • PCV114 SEARCHING THE OPTIMAL TREATMENT MIX STRATEGY WITH A TREATMENT MIX CHART APPROACH-THE CASE OF CHOLESTEROL LOWERING IN SWEDEN

    Nov 1, 2008, 00:00

  • PND29 EFFICIENCY PROFILE IN THE NEUROLOGICAL REFERRALS EFFECTUATE REFERENCE SPECIALISTS- USE CASE-MIX SYSTEM ADJUSTED CLINICAL GROUPS

    Nov 1, 2008, 00:00

  • PMH40 PATIENTS WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER 2-YEAR ASSESSMENT OF IMPACT ON QUALITY OF LIFE AND CLINICAL SEVERITY- RESULTS FROM ADORE STUDY IN FRANCE

    Nov 1, 2008, 00:00

  • PHP54 ANTIBIOTICS CONSUMPTION IN THE REPUBLIC OF SERBIA IN 2004, 2005, 2006 AND 2007

    Nov 1, 2008, 00:00

  • PMS5 PREVALENCE OF FIBROMYALGIA IN GERMANY

    Nov 1, 2008, 00:00

  • PMH61 ADULTS WITH ATTENTION-DEFICIT/ HYPERACTIVITY DISORDER (ADHD) IN GERMANY-PREVALENCE, COMORBIDITIES AND PHARMACOTHERAPY IN PRACTICE

    Nov 1, 2008, 00:00

  • PIN16 COST-EFFECTIVENESS OF A PROPHYLACTIC HUMAN PAPILLOMA VIRUS 16/18 VACCINE FOR 12-YEAR-OLD DUTCH GIRLS

    Nov 1, 2008, 00:00

  • PMH20 ECONOMIC EVALUATION OF PALIPERIDONE ER FOR THE TREATMENT OF SCHIZOPHRENIA IN THE CONTEXT OF BRAZILIAN PUBLIC HEALTH CARE SYSTEM

    Nov 1, 2008, 00:00

  • PCN95 POLICY-MAKING FOR EXPENSIVE INNOVATIVE DRUGS IN FRANCE- ECONOMIC IMPACT AND INFLUENCE ON STAKEHOLDERS! BEHAVIOURS OF POTENTIAL DECISIONS ABOUT TAXANES

    Nov 1, 2008, 00:00

  • PHP8 ADVERSE DRUG REACTIONS IN GERMANY- COST ANALYSIS OF INTERNAL MEDICINE HOSPITALIZATIONS

    Nov 1, 2008, 00:00

  • PCV88 IMPACT OF SINGLE-PILL VS. 2-PILL AMLODIPIN/ATORVASTATIN TREATMENT ON COMPLIANCE- A CZECH PILOT PROJECT ON MEDICATION ADHERENCE

    Nov 1, 2008, 00:00

  • PSY63 PATIENT-REPORTED OUTCOMES (PROS) AND ECONOMICS OF NEUROPATHIC PAIN IN GERMANY

    Nov 1, 2008, 00:00

  • PND20 MEASURING THE IMPACT OF NARCOLEPSY ON QUALITY OF LIFE- A SYSTEMATIC REVIEW

    Nov 1, 2008, 00:00

  • PMS28 COST OF RHEUMATOID ARTHRITIS MODEL PER LEVEL OF DISEASE ACTIVITY IN FRANCE

    Nov 1, 2008, 00:00

  • PMS11 PREVALENCE OF FIBROMYALGIA IN RUSSIA- EARLY RESULTS

    Nov 1, 2008, 00:00

  • MH2 THE SUSTAINED DIAGNOSIS OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER FROM CHILDHOODTO ADULTHOOD- A MEDICAID STUDY

    Nov 1, 2008, 00:00

  • PIH15 HEALTH-RELATED QUALITY OF LIFE IN ADOLESCENTS WITH THE PRADER-WILLI SYNDROME

    Nov 1, 2008, 00:00

  • PSS18 SENSITIVE SKINS IN SWITZERLAND- AN EPIDEMIOLOGICAL APPROACH

    Nov 1, 2008, 00:00

  • PCN99 AVAILABILITY AND SPATIAL DISTRIBUTION OF ONCOLOGY SPECIFIC RESOURCES IN GREECE

    Nov 1, 2008, 00:00

  • PDB48 NOT ALL ROADS LEAD TO ROME-A REVIEW OF QUALITY OF LIFE MEASUREMENT IN DIABETES

    Nov 1, 2008, 00:00

  • PMC54 THE RIGOUR, FLEXIBILITY AND EASE OF IMPLEMENTATION OF SYSTEMATIC SEARCH STRATEGIES-DOWE NEED AN INDUSTRY STANDARD METHODOLOGY?

    Nov 1, 2008, 00:00

  • DB2 IMPACT OF OVERWEIGHT OR OBESITY ON TREATMENT COSTS IN PATIENTS WITH DIABETES IN THE USA- QUANTILE REGRESSION APPROACH

    Nov 1, 2008, 00:00

  • PSY60 PREDICTING FACTORS FOR METABOLIC SYNDROME AMONG US ADOLESCENTS 12-17YEARS OF AGE

    Nov 1, 2008, 00:00

  • PHP5 HEALTH LITERACY-AN ECONOMIC PERSPECTIVE- A SYSTEMATIC REVIEW

    Nov 1, 2008, 00:00

  • PCN66 HOW COSTLY IS RADIOTHERAPY WITH PARTICLES? COST ANALYSIS OF EXTERNAL BEAM RADIOTHERAPY WITH CARBON IONS, PROTONS AND CONVENTIONAL PHOTONS

    Nov 1, 2008, 00:00

  • PUK16 EXPLORING THE IMPACT OF CHANGES IN NEUROGENIC URINARY INCONTINENCE FREQUENCY AND CONDITION SPECIFIC QUALITY OF LIFE ON PREFERENCE-BASED OUTCOMES

    Nov 1, 2008, 00:00

  • PCN81 CROSS-CULTURAL ADAPTATION INTO SPANISH AND ITEM REDUCTION OF THE UCLA-PROSTATIC CANCER INDEX (UCLA-PCI)- A SPECIFIC HEALTH RELATED QUALITY OF LIFE (HRQOL) QUESTIONNAIRE FOR PROSTATIC CANCER

    Nov 1, 2008, 00:00

  • PCV102 COST-EFFECTIVENESS OF MANAGING ORAL ANTICOUAGULATION (OAC) AFTER CATHETER ABLATION FOR A TRIAL FIBRILLATION (PAAF) WITH IMPLANTABLE CARDIAC MONITORS (ICMS)

    Nov 1, 2008, 00:00

  • PCN104 A BUDGET IMPACT MODEL FOR THE INTRODUCTION OF PANITUMUMAB, A NEWTHERAPY FOR THE MANAGEMENT OF METASTATIC COLORECTAL CANCER (MCRC) IN GREECE

    Nov 1, 2008, 00:00

  • PDB11 POTENTIAL IMPACT OF LIPID CONTROL AND SUBSEQUENT CARDIOVASCULAR (CV) RISK REDUCTION INT2DM POPULATION TREATED WITH ORAL COMBINATION THERAPY (OCT) RECAP-DM STUDY

    Nov 1, 2008, 00:00

  • PDB66 INSULIN GLARGINE UTILIZATION IN REAL-LIFE-EFFICACY OF A REGIMEN BASED ON INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES PREVIOUSLY ON NPH INSULIN IN CLINICAL PRACTICE IN SPAIN

    Nov 1, 2008, 00:00

  • PIN2 ASSESSING ANTIMICROBIAL SUCCESS RATES IN THE TREATMENT OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) COMPLICATED SKIN AND SOFT TISSUE INFECTIONS (CSSTI)-A BAYESIAN META-ANALYSIS

    Nov 1, 2008, 00:00

  • MS1 PREVALENCE OF FIBROMYALGIA IN EUROPE- A TIP OF THE ICEBERG.RESULTS FROM A LARGE-SCALE SURVEY

    Nov 1, 2008, 00:00

  • PDB50 CONCEPTUAL DEVELOPMENT OF A PATIENT SELF-ASSESSMENT TOOL TO IMPROVE PATIENT-CLINICIAN COMMUNICATION ON THE DAILY MANAGEMENT OF TYPE 2 DIABETES

    Nov 1, 2008, 00:00

  • PCV7 CLINICAL EFFECTIVENESS OF BOSENTAN, EPOPROSTENOL, ILOPROST, SILDENAFIL AND TREPROSTINIL IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION-A SYSTEMATIC REVIEW

    Nov 1, 2008, 00:00

  • PCN77 DERIVING UTILITY VALUES FROM THE GENERAL POPULATION FOR INDUCTION CHEMOTHERAPY ADMINISTERED BEFORE CONCURRENT CHEMOTHERAPY-RADIATION THERAPY IN THE TREATMENT OF HEAD AND NECK CANCER

    Nov 1, 2008, 00:00

  • PHP50 UNIVERSAL STEPS IN PERFORMING EARLY-STAGE MEDICAL TECHNOLOGY ASSESSMENT

    Nov 1, 2008, 00:00

  • PIN44 IMPACT OF ETRAVIRINE ON HOSPITALIZATIONS AND HOSPITAL RELATED COSTS IN BELGIUM- 48-WEEK FINDINGS FROM POOLED DUETTRIALS

    Nov 1, 2008, 00:00

  • PMC39 WHAT DOES ACCEPTABILITY MEAN FOR PATIENTS AND HOW SHOULD IT BE MEASURED? QUALITATIVE STEPS FOR THE DEVELOPMENT OF A NEW MEASUREMENT INSTRUMENT IN PHARMACIES

    Nov 1, 2008, 00:00

  • PMH59 MODELLING THE ANTIDEPRESSANTS MARKET BEHAVIOUR AFTER PATENT EXPIRIES

    Nov 1, 2008, 00:00

  • PMH47 QUANTIFYING UNMET NEEDS AMONG PATIENTS WITH DEPRESSION USING AN SSRI OR SNRI ACROSS FIVE EUROPEAN COUNTRIES USING PATIENT-REPORTED SURVEY DATA

    Nov 1, 2008, 00:00

  • PRS14 COST OF ALLERGIC RHINITIS IN PEDIATRIC PATIENTS IN MEXICO

    Nov 1, 2008, 00:00

  • PG118 DIRECT MEDICAL COSTS OF CROHNS DISEASE IN SPAIN- A MARKOV MODEL

    Nov 1, 2008, 00:00

  • PCV6 EFFECTIVENESS OF CLOPIDOGREL IN ADDITION TO ASPIRIN COMPARED TO ASPIRIN ALONE AFTER ACUTE CORONARY SYNDROME

    Nov 1, 2008, 00:00

  • PMH26 ONE YEAR PROSPECTIVE HEALTH CARE AND NON-HEALTH CARE RESOURCES USE AND COST STUDY IN PATIENTS WITH DEMENTIA OF ALZHEIMER TYPE- A SPANISH PERSPECTIVE

    Nov 1, 2008, 00:00

  • PDB63 EFFECTS OF DOSING REGIMEN ON RESOURCE UTILIZATION AND COSTS IN MEDICAID ENROLLED TYPE 2 DIABETES MELLITUS PATIENTS

    Nov 1, 2008, 00:00

  • AR3 TO INVESTIGATE THE BENEFIT OF ANTI-TNF THERAPY ION PHYSICAL AND MENTAL FUNCTIONING VIA THE SHORT FORM-36 QUALITY OF LIFE QUESTIONNAIRE IN PATIENTS WITH RHEUMATOID ARTHRITIS

    Nov 1, 2008, 00:00

  • PRS20 SYSTEMATIC REVIEW OF FIXED-DOSE COMBINATIONS AND UNIT-OF-USE PACKAGING IN PATIENTS WITH HYPERTENSION, DYSLIPIDEMIA, AIDS, ASTHMA AND DIABETES TYPE 2

    Nov 1, 2008, 00:00

  • PCV62 THE BURDEN OF ACUTE CORONARY SYNDROMES IN AUSTRALIA

    Nov 1, 2008, 00:00

  • PIN53 PHARMACY-IMPLEMENTED GUIDELINES ON SWITCHING FROM INTRAVENOUSTO ORAL ANTIBIOTICS- A PROSPECTIVE STUDY IN A TEACHING HOSPITAL

    Nov 1, 2008, 00:00

  • PDB58 PREDICTION MODEL FOR BLOOD GLUCOSE OF TYPE 2 DIABETIC PATIENT

    Nov 1, 2008, 00:00

  • PHP16 OUTHOSPITAL DRUG CONSUMPTION IN MONTENEGRO IN 2007

    Nov 1, 2008, 00:00

  • PHP56 IMPACT OF ICU SEDATION PRACTICE ON PATIENT MORBIDITY, COST AND HOSPITAL RESOURCE USE- A SYSTEMATIC REVIEW

    Nov 1, 2008, 00:00

  • PCV81 AN ECONOMIC EVALUATION OF THE ADDITION OF FIXED-DOSE NIACIN EXTENDED-RELEASE AND SIMVASTATIN THERAPY TO THE MANAGED CARE FORMULARY IN TERMS OF OPTIMAL LIPID VALUE ATTAINMENT

    Nov 1, 2008, 00:00

  • PDB1 THE IMPACT OF INSULIN DETEMIR COMPARED TO NEUTRAL PROTAMINE HAGEDORN INSULIN ON LONG-TERM DIABETES-RELATED COMPLICATIONS- A MODELING ANALYSIS IN TYPE 1 DIABETES PATIENTS IN BELGIUM, FRANCE, GERMANY, ITALY AND SPAIN

    Nov 1, 2008, 00:00

  • PSS40 RESPONSE SHIFT IN A RANDOMIZED CONTROLLED TRIAL OF LOWVISION CARE FOR PATIENTS WITH AGE-RELATED MACULOPATHY

    Nov 1, 2008, 00:00

  • CASE3 A CHANGE IN REIMBURSEMENT STRATEGY IN ICELAND- AIMING AT VALUE-BASED PRICING

    Nov 1, 2008, 00:00

  • CN6 COST-EFFECTIVENESS OF A HUMAN PAPILLOMAVIRUS VACCINE IN REDUCING THE RISK OF CERVICAL CANCER IN IRELAND USING ATRANSMISSION DYNAMIC MODEL

    Nov 1, 2008, 00:00

  • PMS18 COSTS OF TREATMENT OF RHEUMATOID ARTHRITIS WITH BIOLOGICAL DRUGS

    Nov 1, 2008, 00:00

  • PCV40 COST-EFFECTIVENESS OF TARGETING MULTIPLE LIPID PARAMETERS (LDL-C, HDL-C, TG) WITH NIASPANVERSUS A SINGLE LIPID PARAMETER (LDL-C) WITH ZETIA IN PATIENTS RECEIVING ON-GOING STATIN THERAPY

    Nov 1, 2008, 00:00

  • PMH4 EFFICACY AND SAFETY OF ORAL A TYPICAL ANTIPSYCHOTICS FOR SCHIZOPHRENIA- A META-ANALYSIS INCLUDING PALIPERIDONE EXTENDED-RELEASE

    Nov 1, 2008, 00:00

  • PRS38 DEVELOPMENT OF EXPLICIT APPROPRIATENESS CRITERIA FOR THE INDICATION OF ADMISSION FROM PATIENTS WITH ACUTE COPD EXACERBATION

    Nov 1, 2008, 00:00

  • PCV68 IMPACT OF DRUG ELUTING STENTS ON CLINICAL AND ECONOMIC OUTCOMES IN AN UNSELECTED INTERVENTIONAL PRACTICE

    Nov 1, 2008, 00:00

  • PMS43 GOLIMUMAB, A HUMAN ANTI-TNF-ALPHA MONOCLONAL ANTIBODY, SIGNIFICANTLY REDUCES TIME LOST FROM WORK FOR PATIENTS WITH RHEUMATOID ARTHRITIS- POOLED RESULTS FROMTHREE PHASE 3 STUDIES

    Nov 1, 2008, 00:00

  • PG11 THE DEVELOPMENT AND PERFORMANCE OF MODELS TO PREDICT RISK OF LIVER DISEASE DIAGNOSIS FOLLOWING LIVER FUNCTION TESTING IN PRIMARY CARE

    Nov 1, 2008, 00:00

  • PIN55 COST-EFFECTIVENESS OF DARUNAVIR/RITONAVIR 600/100MG BID IN TREATMENT-EXPERIENCED, LPV/R-NAVE, PI-RESISTANT, HIV-INFECTED ADULTS IN THE UNITED KINGDOM, BELGIUM, ITALY AND SWEDEN

    Nov 1, 2008, 00:00

  • MO2 INCORPORATING CALIBRATED MODEL PARAMETERS INTO SENSITIVITY ANALYSES- DETERMINISTIC AND PROBABILISTIC APPROACHES

    Nov 1, 2008, 00:00

  • PMS16 ADALIMUMAB, ETANERCEPT AND INFLIXIMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS-BUDGET IMPACT ANALYSIS ON POLISH NATIONAL HEALTH FUND

    Nov 1, 2008, 00:00

  • PSY36 EUROPEAN ECONOMIC EVALUATION OF OROS HYDROMORPHONE IN THE MANAGEMENT OF SEVERE CHRONIC CANCER AND NON-CANCER PAIN

    Nov 1, 2008, 00:00

  • PCV80 TISSUE ENGINEERING OF VALVEDVENOUS CONDUITS (VVC) VERSUS CONSERVATIVE THERAPY IN PATIENTS WITH CHRONICVENOUS INSUFFICIENCY (CVI). A DECISION ANALYTIC MODEL USING EXPERT ESTIMATED UTILITIES BASED ON DERIVED DATA FROM ANIMAL STUDIES AS ...

    Nov 1, 2008, 00:00

  • PCN110 STATISTICAL METHODOLOGY IS CRUCIAL IN PROGNOSTIC FACTOR ANALYSIS OF HEALTH-RELATED QUALITY OF LIFE

    Nov 1, 2008, 00:00

  • PHP4 PATIENT PREFERENCES TOWARD HEALTH SERVICES PROVIDED BY THE GENERAL PRACTIONER

    Nov 1, 2008, 00:00

  • PCV86 COMPARISON OF PERSISTENCE AND ADHERENCE BETWEEN PRASUGREL AND CLOPIDOGREL IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROMES AND PERCUTANEOUS CORONARY INTERVENTIONS

    Nov 1, 2008, 00:00

  • PSY31 ECONOMIC IMPACT OF THE FABRY-ANDERSON DISEASE TREATMENT

    Nov 1, 2008, 00:00

  • PMS62 DISCONTINUATION RATE OF THE IST AND IIND ANTI-TUMOR NECROSIS FACTORTHERAPIES IN PATIENTS WITH RHEUMATOID ARTHRITIS IN ITALY

    Nov 1, 2008, 00:00

  • QL8 COMPARISON OF CANCER-RELATED FATIGUE USING A ONE- VERSUS FOUR-WEEK RECALL PERIOD

    Nov 1, 2008, 00:00

  • PSS4 RESTOR VERSUS ACRILISA ND-YAG LASER INCIDENCE RATE COMPARISON ONE YEAR AFTER SURGERY

    Nov 1, 2008, 00:00

  • PCN39 EXPLORATORY COST EFFECTIVENESS ANALYSIS OF BEVACIZUMAB IN ADDITION TO FOLFOX-4 IN THE ADJUVANT TREATMENT OF STAGE III COLON CANCER- A UK PERSPECTIVE

    Nov 1, 2008, 00:00

  • PIH10 THE COST EFFECTIVENESS OF SCHEDULED MAINTENANCE TREATMENT WITH INFLIXIMAB AMONG PAEDIATRIC PATIENTS WITH CROHNS DISEASE IN SCOTLAND

    Nov 1, 2008, 00:00

  • PMC18 CONCEPTUALISING DISEASE- BUILDING UNIFYING MODELS TO SUPPORT THE DEVELOPMENT OF PROS AND COST-EFFECTIVENESS ANALYSES. A CASE STUDY IN ALZHEIMER-S DISEASE (AD)

    Nov 1, 2008, 00:00

  • PCN41 ECONOMIC EVALUATION OF TRASTUZUMAB FOR THE ADJUVANT TREATMENT OF HER2 POSITIVE EARLY BREAST CANCER IN THE NETHERLANDS

    Nov 1, 2008, 00:00

  • PMS48 PATIENT EXPECTATIONS IN HEALTH RELATED QUALITY OF LIFE OUTCOMES IN TOTAL JOINT REPLACEMENT

    Nov 1, 2008, 00:00

  • PRS42 SMOKING-CESSATION ACROSS BORDERS- TRANSFERABILITY OF COST-EFFECTIVENESS RESULTS

    Nov 1, 2008, 00:00

  • PSS39 QUALITY OF LIFE IN MODERATE TO SEVERE PSORIASIS PATIENTS IN SPAIN

    Nov 1, 2008, 00:00

  • PCN90 DEVELOPMENT OF AN EFFECTIVE HOME PALLIATIVE CARE SYSTEM ADOPTING A MULTIDISCIPLINARYTEAM APPROACH-SATISFACTION OF THE PATIENTS FAMILY FOR THE DOMICILIARY PALLIATIVE CARE 'OKAYAMA' MODEL

    Nov 1, 2008, 00:00

  • PHC5 A COST-EFFECTIVENESS ANALYSIS OF RHBMP-2 IN SPINE FUSION SURGERY IN THE NETHERLANDS

    Nov 1, 2008, 00:00

  • PCN42 A SENSITIVITY ANALYSIS ON THE COST UTILITY OF BEVACIZUMAB, CAPECITABINE, AND OXALIPLATIN COMPARED WITH FOLFOX FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER (CRC)- A UK PERSPECTIVE

    Nov 1, 2008, 00:00

  • PMC44 THE SIGNIFICANCE OF PATIENT-REPORTED OUTCOMESTO FACILITATE MARKET ACCESS DURING A PRODUCT LIFECYCLE

    Nov 1, 2008, 00:00

  • PG138 RESULTS OF ALEGRIA, A REAL LIFE EVALUATION OF GERD IMPACT OF SYMPTOM ASSESSMENT IN BELGIUM

    Nov 1, 2008, 00:00

  • PIH3 EPIDEMIOLOGICAL SURVEILLANCE OF CONGENITAL MALFORMATIONS IN 52,744 BIRTHS COLOMBIAN BETWEEN APRIL 2001 AND JANUARY 2008

    Nov 1, 2008, 00:00

  • DB3 HEALTH CARE RESOURCE UTILIZATION AND COSTS IN INSULIN-DEPENDENT PATIENTS WITH TYPE 2 DIABETES UNDER REALWORLD CONDITIONS IN GERMANY- LIVE-SPP STUDY

    Nov 1, 2008, 00:00

  • PMC37 CHALLENGES OF TRANSLATING AND LINGUISTICALLY VALIDATING PRO MEASURES INTO SLAVIC LANGUAGES

    Nov 1, 2008, 00:00

  • PHP7 COMPARING THE ACTUAL HOSPITAL COST OF A PATIENT WITH OESOPHAGEAL CANCERTO NORMATIVE DRG REIMBURSEMENT

    Nov 1, 2008, 00:00

  • PMC27 DO LIKERT-TYPE SCALE AND VISUAL ANLOGUE SCALE MEASURE THE SAME QUALITY OF LIFE?

    Nov 1, 2008, 00:00

  • PSY20 THE COST EFFECTIVENESS OF DULOXETINE IN THE TREATMENT OF FIBROMYALGIA IN THE NHS IN SCOTLAND

    Nov 1, 2008, 00:00

  • HP2 NEONATAL INTENSIVE CARE UNITS (NICUS) IN GREECE- FACTORS AFFECTING THE LENGTH OF STAY (LOS) OF THE NEONATES AND THE DRIVERS OF COST

    Nov 1, 2008, 00:00

  • PMS17 THE ECONOMIC IMPLICATIONS OF ACHIEVING TREATMENT RESPONSE IN PATIENTS WITH RHEUMATOID ARTHRITIS

    Nov 1, 2008, 00:00

  • PSS58 A SCORING SYSTEM FOR QUALITY OF CARE EVALUATION. A COMMUNITY-BASED STUDY OF CHRONIC LEG ULCERS IN NORTH GERMANY

    Nov 1, 2008, 00:00

  • PIN43 DIFFERENCE IN HEALTH CARE UTILIZATION IN EUROPE BETWEENTREATMENT-NAVE PATIENTS WITH CHRONIC HEPATITIS C AND PATIENTSWHO FAILED PRIOR THERAPY

    Nov 1, 2008, 00:00

  • PHP60 COMPARISON OF THE HEALTH ECONOMIC GUIDELINES OF THE CZECH REPUBLIC, HUNGARY, POLAND AND THE SLOVAK REPUBLIC

    Nov 1, 2008, 00:00

  • AR1 PRODUCTIVITY LOSS AT WORK IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS

    Nov 1, 2008, 00:00

  • PMH14 THE COST-EFFECTIVENESS OF QUETIAPINE EXTENDED-RELEASE VERSUS OLANZAPINE FOLLOWING GENERIC RISPERIDONE IN PATIENTS WITH FIRST EPISODE SCHIZOPHRENIA

    Nov 1, 2008, 00:00

  • MD1 HEALTH ECONOMIC ANALYSIS OF CONTINUOUS SUBCUTANEOUS INSULIN INFUSION COMPARED TO MULTIPLE DAILY INJECTIONS FOR THE TREATMENT OF TYPE 1 DIABETES IN POLAND

    Nov 1, 2008, 00:00

  • PRS18 DIFFERENCES IN TREATMENT COSTS AND RESOURCE UTILIZATION AMONG COPD PATIENTS TREATED WITH ALBUTEROL MDI OR LEVALBUTEROL MDI

    Nov 1, 2008, 00:00

  • PMC34 METHODOLOGIES FOR ASSESSING AND DEMONSTRATING DATA SATURATION IN QUALITATIVE INQUIRY SUPPORTING PATIENT-REPORTED OUTCOMES RESEARCH

    Nov 1, 2008, 00:00

  • PCN14 A MODELTO DEMONSTRATE THE COMPARATIVE COSTS BETWEEN PANITUMUMAB AND CETUXIMAB FOR THIRD-LINE METASTATIC COLORECTAL CANCER PATIENTS IN ITALY

    Nov 1, 2008, 00:00

  • PCV105 STATIN PRESCRIBING IN THE CITY OF ZAGREB (2001-2006) AND THEIR ROLE IN SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS

    Nov 1, 2008, 00:00

  • PMC3 OVERCOMING THE FINAL HURDLE- COMMUNICATING THE COST EFFECTIVENESS OF A NEW DRUG

    Nov 1, 2008, 00:00

  • PDB44 TREATMENT COMPLIANCE AND ILLNESS KNOWLEDGE IN DIABETIC PATIENTS ATTENDED IN SPANISH PRIMARY CARE CENTRES

    Nov 1, 2008, 00:00

  • PCN69 PHARMACOECONOMIC ANALYSIS OF THE ADDITION OF RITUXIMAB TO FIRST-LINE CHEMOTHERAPY TREATMENT REGIMENS IN SPANISH PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA

    Nov 1, 2008, 00:00

  • PSY18 COST-EFFECTIVENESS OF FENTANYL ITS (IONSYSTM) IN POST-OPERATIVE PAIN MANAGEMENT- A FINNISH HOSPITAL PERSPECTIVE ANALYSIS

    Nov 1, 2008, 00:00

  • PSS46 MELANOTIC TUMOURS- EVALUATION OF SELF-PERCEIVED STRESS AND QUALITY OF LIFE

    Nov 1, 2008, 00:00

  • PMS27 COST CONSEQUENCE ANALYSIS OF RITUXIMAB TREATMENT FOR RHEUMATOID ARTHRITIS IN ISRAEL

    Nov 1, 2008, 00:00

  • PND30 NATIONAL GUIDELINE FOR MULTIPLE SCLEROSIS TREATMENT IN BRAZILIAN PUBLIC HEALTH- AN ANALYSIS OF TREATMENT PATTERNS AND BUDGET IMPACT

    Nov 1, 2008, 00:00

  • PIN39 INPATIENT COSTS AND OUTCOMES ASSOCIATED WITH HEPATITIS C, HUMAN IMMUNODEFICIENCY VIRUS, AND CO-INFECTION WITH BOTH IN THE UNITED STATES

    Nov 1, 2008, 00:00

  • PMC12 MODELLING THE VALUE FOR MONEY OF CLINICAL PRACTICE CHANGE- A STOCHASTIC APPLICATION IN DIABETES CARE

    Nov 1, 2008, 00:00

  • PMH15 COST-EFFECTIVENESS OF QUETIAPINE IN COMBINATION WITH LITHIUM/DIVALPROEX IN MAINTENANCE TREATMENT OF BIPOLAR I DISORDER

    Nov 1, 2008, 00:00

  • EE2 STANDARDIZED TYPE 2 DIABETES COMPLICATION COSTS FROM US COMMERCIAL PAYERS TO BE USED IN MODELING THE LONG-TERM ECONOMIC OUTCOMES OF DIABETES COMPLICATIONS

    Nov 1, 2008, 00:00

  • PMS21 COST-EFFECTIVENESS SIMULATION MODEL OF ABATACEPT VERSUS RITUXIMAB IN RHEUMATOID ARTHRITIS IN FRANCE

    Nov 1, 2008, 00:00

  • PSS30 COST OF SPECTACLES AFTER CATARACT SURGERY IN THE NETHERLANDS

    Nov 1, 2008, 00:00

  • PCV61 INFLUENCE THE CO-MORBIDITY AND DIRECT COSTS OF STROKETO POPULATION SETTING AND IN CLINICAL PRACTICE

    Nov 1, 2008, 00:00

  • PIN38 THE ECONOMIC BURDEN OF HCV AND HBV CO-INFECTION- EVIDENCE FROM UNITED STATES MANAGED CARE DATA

    Nov 1, 2008, 00:00

  • PCV112 STATINS USE IN PATIENTS WITH A RECENT ISCHEMIC STROKE- RESULTS FROM THE STROKE ANALYZER DATABASE

    Nov 1, 2008, 00:00

  • PCASE1 ESTABLISHMENT OF A COST-EFFECTIVENESS (CE) THRESHOLD AT KING HUSSEIN CANCER CENTER- IMATINIB IN CHRONIC MYELOGENOUS LEUKEMIA (CML)

    Nov 1, 2008, 00:00

  • PSS36 THE DESCRIPTIVE EPIDEMIOLOGY AND OUTCOME OF HOSPITALISATIONS FOR PSORIASIS IN THE UNITED KINGDOM

    Nov 1, 2008, 00:00

  • PSS45 A TOPICAL DERMATITIS- EVALUATION OF SELF-PERCEIVED STRESS AND QUALITY OF LIFE

    Nov 1, 2008, 00:00

  • PG110 ONCE DAILY MESALAZINE FOR MAINTAINING REMISSION IS COST-SAVING COMPARED TO TWICE DAILY MESALAZINE- AN ECONOMIC EVALUATION BASED ON THE PODIUM RANDOMISED CONTROLLED TRIAL

    Nov 1, 2008, 00:00

  • PMS50 FRACTURE INCIDENCE AND CHANGES IN QUALITY OF LIFE AND BACK PAIN INWOMEN WITH OSTEOPOROSIS TREATED WITH TERIPARATIDE- EUROPEAN FORSTEO OBSERVATIONAL STUDY (EFOS) 18 MONTH RESULTS FROM PATIENTS ENROLLED IN FRANCE

    Nov 1, 2008, 00:00

  • PMS30 COSTS AVOIDED BY DIAGNOSING FIBROMYALGIA IN FRENCH PATIENTS

    Nov 1, 2008, 00:00

  • PCN22 AN ECONOMIC EVALUATION OF CAPECITABINE/CISPLATIN PLUS 5-FU/CISPLATIN REGIMENS IN TREATMENT OF ADVANCED GASTRIC CANCER IN SPAIN

    Nov 1, 2008, 00:00

  • PUK1 CLINICAL ATTITUDES ON CHRONIC GRAFT DYSFUNCTION- THE ICEBERG STUDY

    Nov 1, 2008, 00:00

  • PDB68 LONG-TERM COST-EFFECTIVENESS OF INSULIN DETEMIR COMPARED TO NEUTRAL PROTAMINE HAGEDORN INSULIN IN PATIENTS WITH TYPE 1 DIABETES USING A BASAL-BOLUS REGIMEN IN SWEDEN

    Nov 1, 2008, 00:00

  • PHP12 THE BELGIAN REIMBURSEMENT PROCEDURE (BRP)-ARE ADDED THE RAPEUTIC VALUE (ATV) AND ICER AFFECTING THE DRUG REIMBURSEMENT DECISION (DRD)?

    Nov 1, 2008, 00:00

  • PIH7 ECONOMIC ANALYSIS OF TREATMENT WITH IUI-COH VERSUS 6 MONTHS DELAY OF TREATMENT IN COUPLES WITH UNEXPLAINED SUBFERTILITY

    Nov 1, 2008, 00:00

  • PHP43 GREEK HOSPITALS SUPPLY CHAIN MANAGEMENT

    Nov 1, 2008, 00:00

  • PMH38 CAN PATIENTS WITH SCHIZOPHRENIA COMPLETE A CONJOINT ANALYSIS? EVIDENCE FROM GERMANY

    Nov 1, 2008, 00:00

  • PDB24 A COST-EFFECTIVENESS ANALYSIS OF IRBESARTAN IN THE TREATMENT OF HYPERTENSIVE PATIENTS WITH DIABETIC RENAL DISEASE

    Nov 1, 2008, 00:00

  • PMS59 RESTORATIVE EFFECT OF SLEEP- VALIDATION OF THE SQA (SLEEP QUALITY ASSESSMENT)

    Nov 1, 2008, 00:00

  • CASE1 IMPLEMENTATION OF TRANSPARENT PROCESS OF DRUG REIMBURSEMENT DECISIONS IN POLAND

    Nov 1, 2008, 00:00

  • PMS19 COST-EFFECTIVENESS OF USING ETANERCEPT AS FIRST LINE IN SEVERE AND HIGHLY ACTIVE RHEUMATOID ARTHRITIS (RA)

    Nov 1, 2008, 00:00

  • PUK13 EXPANDED CRITERIA DONORS IN RENAL TRANSPLANTATION- RESULTS OF ECONOMIC EVALUATION

    Nov 1, 2008, 00:00

  • PMH43 THE SPANISH VERSION OF THE TOOL QUESTIONNAIRE- A USEFUL MEASURE FOR EVALUATING THE HRQOL AND UTILITIES FROM SCHIZOPHRENIC AND BIPOLAR PATIENTS

    Nov 1, 2008, 00:00

  • PMC25 IS THE EQ-5D QUESTIONNAIRE A PREDICTOR OF MORTALITY AND HOSPITALIZATION IN A GENERIC ELDERLY POPULATION?

    Nov 1, 2008, 00:00

  • PSS43 A TOPIC DERMATITIS AND THERMAL THERAPY- EVALUATION OF MEDICAL SERVICE

    Nov 1, 2008, 00:00

  • PSY57 USE OF AN ADMINISTRATIVE DATABASE TO ESTIMATE THE NUMBER OF HOSPITAL ADMISSIONS FOR IMMUNE THROMBOCYTOPENIC PURPURA AND ITS ECONOMIC BURDEN IN FRANCE

    Nov 1, 2008, 00:00

  • AR2 A COST EFFECTIVENESS ANALYSIS OF INFLIXIMAB TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) IN SWEDEN, BASED ON DATA FROM THE STURE REGISTRY

    Nov 1, 2008, 00:00

  • PIN33 COST-MINIMIZATION ANALYSIS OF DAPTOMYCIN FOR MRSA SKIN AND SOFT TISSUES INFECTIONS IN BRAZILIAN PRIVATE SECTOR

    Nov 1, 2008, 00:00

  • PMS46 DEVELOPMENT OF A SPECIFIC TOOL TO EVALUATE WOMENS ADHERENCE TO OSTEOPOROSIS TREATMENT

    Nov 1, 2008, 00:00

  • PCN67 COST UTILITY ANALYSIS OF ALEMTUZUMAB COMPARED TO CHLORAMBUCIL IN UNTREATED PATIENTS WITH HIGH-RISK (17P-) CHRONIC LYMPHOCYTIC LEUKEMIA IN THE UNITED KINGDOM

    Nov 1, 2008, 00:00

  • PIH5 INCIDENCE OF MAJOR MALFORMATIONS IN INFANTS FOLLOWING ANTIDEPRESSANT EXPOSURE IN PREGNANCY- RESULTS OF A LARGE PROSPECTIVE COHORT STUDY

    Nov 1, 2008, 00:00

  • PMS15 LEFLUNOMIDE IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN POLAND-A BUDGET IMPACT ANALYSIS

    Nov 1, 2008, 00:00

  • PRS32 SYMPTOMS AND IMPACT OF SYMPTOMS AS REPORTED BY ASTHMA PATIENTS

    Nov 1, 2008, 00:00

  • PCV71 COST-UTILITY ANALYSIS IN PATIENTS WITH DRUG REFRACTORY CONCOMITANT A TRIAL FIBRILLATION IN SPAIN

    Nov 1, 2008, 00:00

  • PMC38 INFLUENCE OF DEMOGRAPHIC AND CULTURAL PREDICTORS ON EQ-5D VALUE SET IN THE POLISH POPULATION

    Nov 1, 2008, 00:00

  • PCV63 CO-MORBIDITY AND DIRECT COSTS ACCORDING THE CARDIOVASCULAR RISK LEVEL IN A SPANISH POPULATION SETTING

    Nov 1, 2008, 00:00

  • PCN108 DEVELOPMENT OF AN INTERACTIVE MODEL OF FINANCIAL ACCESS TO CANCERTHERAPY

    Nov 1, 2008, 00:00

  • PCV48 ENHANCING SYNCOPE DIAGNOSTICS- COST-EFFECTIVENESS ANALYSIS OF AN IMPLANTABLE LOOP RECORDER STRATEGY VERSUS THE STANDARD OF CARE

    Nov 1, 2008, 00:00

  • PSY19 MEDICAL AND COST EFFECTIVENESS OF BARIATRIC SURGERY IN OBESITY. RESULTS OF AN HTA COMMISIONED BY THE GERMAN AGENY FOR HEALTHTECHNOLOGY ASSESSMENT

    Nov 1, 2008, 00:00

  • PCN25 COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB THERAPY IN EARLY HER-2 POSITIVE BREAST CANCER PATIENTS- THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM CASE

    Nov 1, 2008, 00:00

  • PHP19 REGIONAL MARKET ACCESS IN EQUALITIES FOR NEW ONCOLOGY DRUGS IN SPAIN

    Nov 1, 2008, 00:00

  • PHP36 PERFORMANCE OF YOUR 5-STAR HOSPITALS

    Nov 1, 2008, 00:00

  • PCV79 ECONOMIC EVALUATION OF IRBESARTAN IN GREECE

    Nov 1, 2008, 00:00

  • PCN13 BUDGET IMPACT ANALYSIS OF THE CONTINUATION OF DOCETAXEL REIMBURSEMENT IN THE NEOADJUVANT THERAPY OF LOCALLY ADVANCED BREAST CANCER AND PALLIATIVE THERAPY OF METASTATIC BREAST CANCER IN POLAND

    Nov 1, 2008, 00:00

  • PCV25 BUDGET IMPACT ANALYSIS OF THROMBOLYSIS FOR STROKE- A DISCRETE EVENT SIMULATION MODEL

    Nov 1, 2008, 00:00

  • PMC36 AN INVESTIGATION OF FACTORIAL STRUCTURE OF SF-36V2 IN THE US GENERAL POPULATION-THE APPLICATION OF CONFIRMATORY FACTOR ANALYSIS THROUGH STRUCTURAL EQUATION MODELLING

    Nov 1, 2008, 00:00

  • PSY35 COST-EFFECTIVENESS ANALYSIS OF THE EPOETIN TREATMENT IN PATIENTS WITH ANEMIA INDUCED BY CHEMOTHERAPY, EPICOST STUDY PRELIMINARY RESULTS (ONVIDA GROUP)

    Nov 1, 2008, 00:00

  • PSS32 COST-EFFECTIVENESS ANALYSIS OF THE FIXED COMBINATION GLAUCOMA MEDICATIONS BRIMONIDINE/TIMOLOL AND DORZOLAMIDE/TIMOLOL IN 10 EUROPEAN COUNTRIES

    Nov 1, 2008, 00:00

  • PCN63 METASTATIC COLORECTAL CANCER- MEDICAL COSTS OF FIRST LINE INFUSIONAL 5-FLUOROURACIL OR ORAL CAPECITABINE IN ITALIAN PATIENTS

    Nov 1, 2008, 00:00

  • PSS55 USTEKINUMAB REDUCESWORK LIMITATIONS, INCREASES WORK PRODUCTIVITY AND DECREASESWORKDAYS MISSED DUETO PSORIASIS IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS

    Nov 1, 2008, 00:00

  • PIN23 COST-EFFECTIVENESS ANALYSIS OF 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN TAIWAN- TRANSMISSION DYNAMIC MODEL-BASED EVALUATIONS

    Nov 1, 2008, 00:00

  • CN4 YEARS OF POTENTIAL LIFE LOST AND PRODUCTIVITY COSTS DUETO CANCER MORTALITY AND FOR SPECIFIC CANCER SITES WHERE HPV MAY BE A RISK FACTOR FOR CARCINOGENESIS-UNITED STATES, 2003

    Nov 1, 2008, 00:00

  • PCN93 THE IMPACT OF A COST ATTRIBUTE ON PREFERENCES

    Nov 1, 2008, 00:00

  • PDB34 MONITORING OF TREATMENT COSTS AFTER REIMBURSEMENT DECISION- SOMATOSTATIN ANALOGUES FOR ACROMEGALY

    Nov 1, 2008, 00:00

  • PIN29 EFFECTIVENESS AND COST-EFFECTIVENESS OF HEPATITIS C SCREENING-A SYSTEMATIC REVIEW

    Nov 1, 2008, 00:00

  • PCN15 A COST-EFFECTIVENESS ANALYSIS OF IXABEPILONE FOR BREAST CANCER AT ATERTIARY CANCER CENTER

    Nov 1, 2008, 00:00

  • PSY27 HEALTH CARE AND NON-HEALTH CARE RESOURCES UTILIZATION AND RELATED COSTS IN SUBJECTS WITH REFRACTORY PAIN ASSOCIATED TO NECK PAIN- A POST-HOC ANALYSIS OF THE EFFECT OF PREGABALIN IN A 12-WEEK PROSPECTIVE STUDY UNDER ROUTINE MEDICAL PRA ...

    Nov 1, 2008, 00:00

  • PMC4 FEASIBILITY OF CONDUCTING BUDGET IMPACT ANALYSIS IN THE SOCIAL SECURITY INSTITUTION OF TURKEY

    Nov 1, 2008, 00:00

  • PRS9 COST-EFFECTIVENESS MODEL OF MOXIFLOXACIN IN ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS (AECB) IN GERMANY INCLUDING THE EFFECTS OF RESISTANCE

    Nov 1, 2008, 00:00

  • CN5 EXPLORATORY ECONOMIC EVALUATION OF ADJUVANT TREATMENT OF NON-SMALL-CELL LUNG CANCER (NSCLC) WITH BEVACIZUMAB IN ADDITION TO A CISPLATIN-BASED TREATMENT REGIMEN IN THE UNITED KINGDOM

    Nov 1, 2008, 00:00

  • PRS11 COST-EFFECTIVENESS OF INCREASING MAINTENANCE DOSES WITH BUDESONIDE/FORMOTEROL MAINTENANCE RELIEVER THERAPY

    Nov 1, 2008, 00:00

  • HT3 A COMPARISON OF REASONS FOR RECOMMENDATION AND REJECTION IN FOUR HEALTHTECHNOLOGY APPRAISAL SYSTEMS- NICE, SMC, CADTH AND PBAC

    Nov 1, 2008, 00:00

  • PSY47 PATIENT-REPORTED OUTCOMES (PRO) IN SUBJECTS WITH REFRACTORY PAIN ASSOCIATED TO NECK PAIN- A POST-HOC ANALYSIS OF THE EFFECT OF PREGABALIN IN A 12-WEEK PROSPECTIVE STUDY UNDER ROUTINE MEDICAL PRACTICE CONDITIONS

    Nov 1, 2008, 00:00

  • PMC32 METHODS FOR ADDRESSING USE OF PRO INSTRUMENTS IN THE SAME LANGUAGE FOR DIFFERENT COUNTRIES- BEST PRACTICE GUIDELINES FOR DECISION-MAKING AND TRANSLATION OR ADAPTATION

    Nov 1, 2008, 00:00

  • PMS57 VALIDITY AND RESPONSIVENESS OF THE WORK PRODUCTIVITY SURVEY- A NOVEL DISEASE-SPECIFIC INSTRUMENT ASSESSINGWORK PRODUCTIVITY WITHIN AND OUTSIDE THE HOME IN SUBJECTS WITH RHEUMATOID ARTHRITIS

    Nov 1, 2008, 00:00

  • PDB41 COST-EFFECTIVENESS OF SOMATROPIN (NORDITROPIN) FOR THE TREATMENT OF GROWTH HORMONE DEFICIENT (GHD) CHILDREN IN A UK SETTING

    Nov 1, 2008, 00:00

  • PCV4 COMPARISON OF THE CLINICAL AND ECONOMIC EFFECTIVENESS OF SIROLIMUS-ELUTING VERSUS BARE-METAL STENTS IN A SUBGROUP OF PATIENTS WITH AND WITHOUT DIABETES

    Nov 1, 2008, 00:00

  • PMH23 THE ECONOMIC EFFECTS OF FASTER TITRATION AND LOWER RELAPSE RATE OF QUETIAPINE XR COMPARED TO QUETIAPINE IR-THE ECONOMICVALUE OF A NEW DRUG FORMULATION

    Nov 1, 2008, 00:00

  • PUK11 A COST-UTILITY ANALYSIS OF SOLIFENACIN 5 MG AND SOLIFENACIN 10 MGVERSUS TOLTERODINE ER 4 MG IN THE PHARMACOLOGICAL TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER (OAB)

    Nov 1, 2008, 00:00

  • PDB2 IMPROVED GLYCAEMIC CONTROL BY SWITCHING FROM INSULIN NPHTO INSULIN GLARGINE- A RETROSPECTIVE OBSERVATIONAL STUDY

    Nov 1, 2008, 00:00

  • PHP48 THE EFFECTS OF NICE HTAS ON PRESCRIPTION VOLUME, AVERAGE RETAIL PRICE AND AVERAGE OUT-OF-POCKET COSTS OF DRUGS DEEMED MEDICALLY NECESSARY FOR MEDICARE PART D REIMBURSEMENT IN THE UNITED STATES

    Nov 1, 2008, 00:00

  • PCN94 COST-EFFECTIVENESS AND PREFERENCE FOR FOLLOW-UP SCENARIOS FOLLOWING BREAST CANCER

    Nov 1, 2008, 00:00

  • PSY9 BUDGET IMPACT OF THE USE OF OROS HYDROMORPHONE ONCE DAILY IN SEVERE CHRONIC PAIN PATIENTS IN THE GERMAN HEALTH CARE SYSTEM

    Nov 1, 2008, 00:00

  • PMS65 GOLIMUMAB, A HUMAN ANTI-TNF-ALPHA MONOCLONAL ANTIBODY, SIGNIFICANTLY IMPROVES SELF-REPORTED PRODUCTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS- RESULTS FROMTHREE PHASE 3 STUDIES

    Nov 1, 2008, 00:00

  • PCV111 COST-ANALYSIS OF DYSLIPOPROTEINAEMIA TREATMENTS WITHIN THE SLOVAK REPUBLIC

    Nov 1, 2008, 00:00

  • PHP24 USE OF THE AMCP FORMAT IN THE U.S.-A NATIONAL SURVEY OF HEALTH PLANS

    Nov 1, 2008, 00:00

  • PDB32 MEDICAL COSTS ATTRIBUTABLE TO OBESITY IN PATIENTS WITH DIABETES MELLITUS AMONG U.S.ADULTS

    Nov 1, 2008, 00:00

  • PMH60 DETERMINANTS OF PRESCRIPTION IN PRIMARY CARE- PROFILE OF PATIENTS PRESCRIBED NEWER ANTIDEPRESSANTS IN THE UNITED KINGDOM

    Nov 1, 2008, 00:00

  • PIH21 EFFICACY OF TREATMENT AND PATIENT SATISFACTION IN TREATMENT OF CLIMACTERIC DISORDERS WITH SOY ISOFLAVONES- FRENCH APPROCH

    Nov 1, 2008, 00:00

  • PIN50 A REVIEW OF THE FACTORS AFFECTING PUBLIC FUNDING OF VACCINES

    Nov 1, 2008, 00:00

  • PCV60 TWO-YEAR HOSPITALIZATION RATES AND ASSOCIATED COSTS IN PATIENTS FROM GERMANY WITH PERIPHERAL ARTERIAL DISEASE- RESULTS FROMTHE REDUCTION OF AT HEROTHROMBOSIS FOR CONTINUED HEALTH (REACH) REGISTRY

    Nov 1, 2008, 00:00

  • PMS51 MAJOR DETERMINANTS OF EUROQOL (EQ-5D) IN PATIENTS WITH RHEUMATOID ARTHRITIS BASED ON A LARGE JAPANESE COHORT IORRA

    Nov 1, 2008, 00:00

  • PMS4 COST-EFFECTIVENESS ANALYSIS OF LEFLUNOMIDE AS A TREATMENT FOR RHEUMATOID ARTHRITIS IN MEXICO

    Nov 1, 2008, 00:00

  • PDB12 ASSOCIATION BETWEEN HYPOGLYCEMIA EPISODES AND CHANGES IN THE SULPHONYLUREA TREATMENT PATTERN IN TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS. RECAP-DM SPANISH COHORT STUDY

    Nov 1, 2008, 00:00

  • PCV110 THE POTENTIAL ECONOMIC IMPACTS OF RECONFIGURING TIA CARE IN THE UK

    Nov 1, 2008, 00:00

  • PCN2 EFFICACY OF LEUPRORELIN 3.75MG COMPARED TO 7.5MG IN THE TREATMENT OF PROSTATE CANCER- SYSTEMATIC REVIEW AND META-ANALYSIS

    Nov 1, 2008, 00:00

  • PMH62 ECONOMIC OUTCOMES OF CO-TREATMENT OF INSOMNIA AND MAJOR DEPRESSIVE DISORDER (MDD) WITH ESZOPICLONE AND FLUOXETINE VERSUS FLUOXETINE TREATMENT ALONE

    Nov 1, 2008, 00:00

  • PCN56 HOSPITAL BURDEN OF DISEASE ASSOCIATED WITH METASTATIC BONE DISEASE (MBD) AND SKELETAL-RELATED EVENTS (SRES) IN PATIENTS WITH BREAST CANCER (BC) AND PROSTATE CANCER (PC) IN SPAIN

    Nov 1, 2008, 00:00

  • PMH49 INTERNATIONAL INVESTIGATION INTO DEPRESSION BASED ON THE STRUCTURED INTERVIEW GUIDE FOR THE HAMILTON DEPRESSION RATING SCALE (SIGH-D) AND THE CLINICIAN RATED INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY (IDS-C)

    Nov 1, 2008, 00:00

  • PCN49 COST-MINIMISATION ANALYSIS OF MAINTENANCE THERAPIES FOR PROSTATE CANCER IN THE UK

    Nov 1, 2008, 00:00

  • PCN97 TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER (MBC) IN THE UKWHO PROGRESS ON TRASTUZUMAB AND HAVE PREVIOUSLY RECEIVED AN ANTHRACYCLINE AND ATAXANE- A NEED FOR EVIDENCE BASED THERAPIES?

    Nov 1, 2008, 00:00

  • PMH57 SECOND GENERATION ANTIPSYCHOTICS AND HOSPITALIZATION IN BIPOLAR DISORDER- A CLAIMS DATA ANALYSIS

    Nov 1, 2008, 00:00

  • PG17 AN ECONOMIC EVALUATION OF THE TWO LEADING ALGINTE THERAPIES IN THE UK- RESULTS FROM A LARGE LONGITUDINAL DATABASE

    Nov 1, 2008, 00:00

  • PHP58 EVALUATING THE PERFORMANCE OF AN INNOVATIVE PUBLIC HEALTH INSURANCE- THE CASE OF A DECENTRALIZED PROVINCE IN ARGENTINA

    Nov 1, 2008, 00:00

  • PDB56 IDENTIFYING FACTORSTHAT AFFECT PATIENTS WILLINGNESS TO PAY FOR INHALED INSULIN

    Nov 1, 2008, 00:00

  • PMS31 OSTEOARTHRITIS AND JOB ABSENTEEISM COSTS- EVIDENCE FROM U.S. NATIONAL SURVEY DATA

    Nov 1, 2008, 00:00

  • PCN9 COST OF MANAGEMENTVERSUS REIMBURSEMENT COST OF THE MANAGEMENT OF PATIENTS WITH SOLIDTUMORS PRESENTING A FEBRILE NEUTROPENIA

    Nov 1, 2008, 00:00

  • PMH37 SWITCHING OF ANTIPSYCHOTICS FROM THE PATIENTS POINT OF VIEW- RESULTS OF A QUANTITATIVE PATIENT SURVEY

    Nov 1, 2008, 00:00

  • PSS17 SENSITIVE SKINS IN BELGIUM- AN EPIDEMIOLOGICAL APPROACH

    Nov 1, 2008, 00:00

  • PND8 COST-EFFECTIVENESS ANALYSIS OF REBIF IN FIRST-LINE RELAPSING REMITTING MULTIPLE SCLEROSIS IN GERMANY

    Nov 1, 2008, 00:00

  • PSY28 HEALTH CARE AND NON-HEALTH CARE RESOURCES UTILIZATION AND RELATED COSTS IN SUBJECTS WITH REFRACTORY PAIN ASSOCIATED TO LOW BACK PAIN- A POST-HOC ANALYSIS OF THE EFFECT OF PREGABALIN IN A 12-WEEK PROSPECTIVE STUDY UNDER ROUTINE MEDICAL ...

    Nov 1, 2008, 00:00

  • PDB21 COST-EFFECTIVENESS OF INSULIN GLARGINE PLUS ORAL ANTIDIABETIC DRUGS (OADS) COMPARED TO PREMIXED INSULIN FOR TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS IN THE CANADIAN PAYER SETTING

    Nov 1, 2008, 00:00

  • PHC12 COMPARING TIME AND SUPPLIES USAGE ASSOCIATED WITH A NEW SKIN CLOSURE DEVICE VS. STANDARD OF CARE WOUND CLOSURE FOR ABDOMINOPLASTY SURGERY IN THE NETHERLANDS

    Nov 1, 2008, 00:00

  • PCN98 RACIAL DIFFERENCES IN MEDICATION-RELATED HEALTH CARE COSTS AND SERVICE UTILIZATION IN HORMONE RECEPTOR POSITIVE PRIMARY BREAST CANCER PATIENTS

    Nov 1, 2008, 00:00

  • CN2 ESTIMATING TARGET POPULATION SIZE FOR BUDGET IMPACT- AN EPIDEMIOLOGICAL MODEL OF BREAST CANCER AND PROGRESSION TO BONE METASTASIS IN THE UK.

    Nov 1, 2008, 00:00

  • PIN17 COST-EFFECTIVENESS OF MASS VACCINATION FOR VARICELLA IN FRANCE WITH MMRV VERSUS MMR

    Nov 1, 2008, 00:00

  • PDB46 DIABETES RELATED QUALITY OF LIFE IN PORTUGUESE PATIENTS

    Nov 1, 2008, 00:00

  • PHP32 COST-BENEFIT ANALYSIS OF PUBLIC HOSPITAL DEVELOPMENT

    Nov 1, 2008, 00:00

  • PCV55 PHARMACOECONOMIC EVALUATION OF TREATMENT WITH PROCORALAN PREPARATION COMPARED TO INVASIVE TREATMENT

    Nov 1, 2008, 00:00

  • PSS51 SCORING AND PSYCHOMETRIC VALIDATION OF THE FREEDOM FROM GLASSES VALUE SCALE (FGVS)

    Nov 1, 2008, 00:00

  • PMC43 USE OF AND COMPLIANCE WITH ELECTRONIC PATIENT REPORTED OUTCOMES WITHIN CLINICAL DRUGTRIALS

    Nov 1, 2008, 00:00

  • PMH5 COMPARISON OF RISK OF UPPER GASTROINTESTINAL HEMORRHAGE AMONG SSRI-USERS WITHIN U.S. MANAGED CARE POPULATION

    Nov 1, 2008, 00:00

  • PND15 THE INDIRECT COST BURDEN OF EPILEPSY IN THE UNITED STATES

    Nov 1, 2008, 00:00

  • QL4 PREDICTING EQ-5D, SF-6D AND 15D UTILITIES FROM EORTC QLQ-C30 DATA

    Nov 1, 2008, 00:00

  • PDB55 PSYCHOMETRIC STRENGTH OF CURRENT TREATMENT SATISFACTION QUESTIONNAIRES IN NON-INSULIN TREATED TYPE 2 DIABETES

    Nov 1, 2008, 00:00

  • PMH12 BUDGET IMPACT OF GENERIC ANTIPSYCHOTIC SUBSTITUTION-A DATABASE ANALYSIS IN GERMANY

    Nov 1, 2008, 00:00

  • PCV104 EVALUATION OF THE PRESCRIPTION PATTERNS OF STATINS THROUGH APPROPRIATE INDICATORS IN TWO ITALIAN LOCAL HEALTH UNITS IN 2004-2006

    Nov 1, 2008, 00:00

  • PSS44 A TOPIC DERMATITIS PSORIASIS- CROSS-EVALUATION OF QUALITY OF LIFE

    Nov 1, 2008, 00:00

  • PCV56 AN ECONOMIC ANALYSIS OF INDUCTION OF LABOR AND EXPECTANT MANAGEMENT INWOMEN WITH PREGNANCYINDUCED HYPERTENSION OR PREECLAMPSIA AT TERM (HYPITAT TRIAL)

    Nov 1, 2008, 00:00

  • PSY11 EONOMIC EVALUATION OF ETANERCEPT COMPARED TO NO SYSTEMIC THERAPY IN THE MANAGEMENT OF LESS SEVERE CHRONIC PLAQUE PSORIASIS IN THE UK

    Nov 1, 2008, 00:00

  • PSY10 ESTIMATION OF THE COSTS FOR A HEREDITARY HEMOCHROMATOSIS GENETIC SCREENING PROGRAMME PER 100.000 INDIVIDUALS UNDER 30YEARS OF AGE IN SPAIN

    Nov 1, 2008, 00:00

  • PSY56 HEALTH-RELATED QUALITY OF LIFE AND PRODUCTIVITY AMONG HEMOPHILIA PATIENTS WITH INHIBITORS

    Nov 1, 2008, 00:00

  • PDB64 EFFECTS OF DOSING REGIMEN ON MEDICATION USE BEHAVIOR IN MEDICAID ENROLLED TYPE 2 DIABETES MELLITUS PATIENTS

    Nov 1, 2008, 00:00

  • PND3 ANTI-EPILEPTIC MEDICATION DRUG FORMULATION CHANGES AND THEIR RELATIONSHIP TO OUTCOMES (AMBULANCE, EMERGENCY DEPARTMENT AND INPATIENT EVENTS)

    Nov 1, 2008, 00:00

  • PMS8 PREVALENCE OF FIBROMYALGIA IN ITALY

    Nov 1, 2008, 00:00

  • PMS71 A COST-EFFECTIVENESS ASSESSMENT OF ABATACEPT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN HUNGARY

    Nov 1, 2008, 00:00

  • PCN58 MEDICAL RESOURCE CONSUMPTION RELATED TO THE TREATMENT OF IRINOTECAN REFRACTORY ADVANCED COLORECTAL CANCER PATIENTS

    Nov 1, 2008, 00:00

  • PSY37 HEALTH AND ECONOMIC CONSEQUENCES OF PATHOGEN TRANSMISSION RISK IN THE TREATMENT OF HAEMOPHILIA A WITH FACTOR VIII

    Nov 1, 2008, 00:00

  • PSY54 UNDERSTANDING PATIENT PERCEPTION OF THE BIOENTERICS INTRAGASTRIC SYSTEM FOR WEIGHT REDUCTION

    Nov 1, 2008, 00:00

  • PMH46 PATIENT PREFERENCES IN ADHD-DISCRETE CHOICE EXPERIMENT

    Nov 1, 2008, 00:00

  • PDB4 GLYCEMIC CONTROL OF TYP-2 DIABETES IN MAKKAH SECURITY FORCES HEALTH CARE CENTER (MSFHCC), SAUDI ARABIA- A DISCRIPTIVE PILOT STUDY

    Nov 1, 2008, 00:00

  • CN7 MODELING THE COST-EFFECTIVENESS OF A NEW AND EXPENSIVE TREATMENT MODALITY IN LUNG CANCER- THE CASE OF PARTICLE THERAPY

    Nov 1, 2008, 00:00

  • PCN35 ECONOMIC EVALUATION OF CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISONE (CHOP) CHEMOTHERAPY REGIME WITH OR WITHOUT RITUXIMAB (R) IN THE 2ND LINE TREATMENT OF FOLLICULAR NON-HODGIN LYMPHOMA

    Nov 1, 2008, 00:00

  • PIH11 COST OF INSOMNIA IN PATIENTS OVER 54 YEARS IN SWEDEN

    Nov 1, 2008, 00:00

  • QL1 AGGREGATION OF DATA FROM MULTIPLE LANGUAGES AND CULTURES- REPORT FROM THE ISPOR TASK FORCE ON TRANSLATION AND LINGUISTIC VALIDATION

    Nov 1, 2008, 00:00

  • PMC52 LINGUISTIC VALIDATION OF THE FRENCH FOR CANADA WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE, GENERAL HEALTHVERSION (WPAI-GH)

    Nov 1, 2008, 00:00

  • PHP51 OTHER HEALTHTECHNOLOGY ASSESSMENT GROUPS OPERATING IN ENGLAND; ITS NOT JUST NICETHAT NEEDS TO BE TAKEN INTO CONSIDERATION

    Nov 1, 2008, 00:00

  • PCV38 EXTENDED PROPHYLAXIS OF VENOUSTHROMBOEMBOLISM (VTE) IN PATIENTS UNDERGOING MAJOR ORTHOPAEDIC SURGERY IN ITALY- A PHARMACOECONOMIC STUDY

    Nov 1, 2008, 00:00

  • PCV117 COMPARATIVE ANALYSIS OF HEALTHTECHNOLOGY ASSESSMENTS (HTA) OF DRUG ELUTING STENTS (DES)

    Nov 1, 2008, 00:00

  • PCV84 HEALTH CARE RESOURCES AND QUALITY OF LIFE IN ACUTE CORONARY SYNDROME PATIENTS IN 2007- FRENCH BASELINE RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL STUDY (APTOR)

    Nov 1, 2008, 00:00

  • IN3 PHARMACOECONOMIC ANALYSIS OF ITRACONAZOLE ORAL SOLUTION IN THE PROPHYLAXIS OF INVASIVE FUNGAL INFECTIONS IN TURKEY

    Nov 1, 2008, 00:00
  • «
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156 (current)
  • 157
  • 158
  • 159
  • 160
  • »